LOGIN
AAOS2018: TissueGene-C demonstrates 52-week efficacy versus placebo in treatment of moderate knee OA
April 2018
AAOS2018: TissueGene-C demonstrates 52-week efficacy versus placebo in treatment of moderate knee OA
Study Type:Randomized Trial
OE Level Evidence:N/A
Journal Level of Evidence:N/A
TissueGene-C (TG-C), a Novel Cell and Gene Therapy for the Treatment of Osteoarthritis
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
CONFERENCE ACE REPORTS
This ACE Report is a summary of a conference presentation or abstract. The information provided has limited the ability to provide an accurate assessment of the risk of bias or the overall quality. Please interpret the results with caution as trials may be in progress and select results may have been presented.
Synopsis
163 patients with Kellgren-Lawrence grade III knee osteoarthritis were randomized to intraarticular treatment with either TissueGene-C or placebo. Patients were assessed for outcome on clinical scores, including the International Knee Documentation Committee (IKDC) score, a visual analog scale, and the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), over 52-week follow-up. ...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.